Schizophrenia is a disabling mental illness that affects millions of Europeans. While antipsychotics alleviate symptoms in one-third of patients, the others are partially or completely refractory to treatment. Although guidelines are available, there is an urgent need to identify objective predictors of treatment outcome to guide personalized treatment. In this project, we will use advanced mathematical methods to analyse clinical and biological data that have been collected during the course of previous studies. We will generate blood-based clinical decision support systems to identify patients at risk of non-responding to conventional antipsychotic monotherapy, patients at risk of relapse following treatment, and patients at risk of developing antipsychotic-induced adverse effects. We will also conduct a placebo-controlled clinical study to assess the efficacy of a new therapeutic protocol and to model its cost-effectiveness when combined with a blood test for selecting patients.